IMNM — Immunome Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1472012 ·
Last close
$17.18
Market Cap
$2.03B
52W High
$30.06
52W Low
$16.41
ADV30
1,476,317
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -90,362,000 | -85,783,000 | 505,527,000 | 212,842,000 | 51,224,000 |
| Jun 2026 | 0 | — | -78,135,000 | -73,127,000 | 565,384,000 | 217,706,000 | 40,301,000 |
| Mar 2026 | 0 | — | -59,331,000 | -53,839,000 | 619,792,000 | 582,693,000 | 31,106,000 |
| Dec 2025 | 0 | — | -72,861,000 | -69,900,000 | 683,188,000 | 653,482,000 | 48,845,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-229,034,000
Investing CF
$-266,857,000
Financing CF
$436,094,000
CapEx
$-18,680,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.54
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-940,913,000
Inventory
—
Receivables
—
ST Investments
$248,740,000
EBIT TTM
$-300,689,000
Pretax Income TTM
$-282,649,000
Interest Exp TTM
—
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-287,496,000
Free Cash Flow
$-159,733,632
Enterprise Value
$1,766,032,128
Total Cash
$461,582,016
Total Debt
$11,385,000
Shares Out
118,072,943
Trailing EPS
$-2.63
Book Value
$4.00
ROE
-78.7%
ROA
-45.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,941,000 | -224,113,000 | -212,394,000 | 683,188,000 | 48,845,000 | 634,343,000 | -190,919,000 |
| Dec 2024 | 9,041,000 | -153,456,000 | -292,963,000 | 240,241,000 | 59,076,000 | 181,165,000 | -110,794,000 |
| Dec 2023 | 14,018,000 | -28,728,000 | -106,806,000 | 148,540,000 | 28,658,000 | 119,882,000 | -7,568,000 |
| Dec 2022 | 0 | -36,901,000 | -36,896,000 | 24,046,000 | 7,393,000 | 16,653,000 | -28,690,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-254,323,000
OpCashFlow TTM
—
Assets (Latest)
$565,384,000
Forward EPS
$-2.55
Max Pain — expiry 2028-01-21
max pain strike: $25.00 · spot: $16.78 · call oi: 409 · put oi: 2,678
Expected Move to 2028-01-21:
±$21.50
(128.13%) —
implied range
$-4.72 –
$38.28
· ATM straddle on $18.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BHVN | Biohaven Ltd. | $2.00B | $13.24 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.06B | $15.40 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.11B | $144.35 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $1.94B | $33.01 | — |
| TRVI | Trevi Therapeutics, Inc. | $1.93B | $13.51 | — |
News headlines (Yahoo Finance, 1h cache)
Immunome to Present at Upcoming Investor Conferences
2026-11-18 12:30 · Yahoo
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 21:02 · Yahoo
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:00 · Yahoo
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
2026-11-04 14:01 · Yahoo
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know
2026-11-04 13:55 · Yahoo
Immunome Stock Gets EMA Review For Desmoid Tumor Drug
2026-11-02 23:14 · Yahoo
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 12:30 · Yahoo
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
2026-10-30 11:30 · Yahoo
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
2026-10-26 11:00 · Yahoo
Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus
2026-10-13 22:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.